Unpacking Controversies in CLL Treatment

Описание: At The HemOnc Pulse Live! in Austin, TX (May 2025), Dr. Ryan W. Jacobs, clinical director of the Lymphoma Division at Atrium Health Levine Cancer and associate professor at Wake Forest University School of Medicine, explored the rapidly evolving treatment landscape for chronic lymphocytic leukemia (CLL).

Dr. Jacobs reviewed the shift from traditional chemoimmunotherapy to BTK inhibitors as indefinite therapy, and highlighted the growing role of venetoclax-based fixed-duration regimens, which can provide long treatment-free intervals while reducing toxicity and improving quality of life. He also discussed emerging oral doublet and triplet therapies that combine BTK and BCL-2 inhibition, offering patients more convenient and durable options.

Key clinical trial insights included findings from the AMPLIFY trial, showing a progression-free survival benefit with acalabrutinib, especially for patients with unmutated disease, and exploring the potential of triplet therapy to deepen remissions. Using clear analogies, Dr. Jacobs contrasted indefinite therapy as a marathon versus fixed-duration therapy as a sprint, emphasizing patient-centered outcomes.

Stay up to date with the latest advances in CLL treatment and learn how evolving strategies are shaping patient care.